Related scientific articles (all)

Targeted therapies of solid cancers: new options, new challenges.

Authors : Awada A, Aftimos P
Year : 2013
Journal : Curr Opin Oncol
Volume : 25(3)
Pages : 296-304

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO.

Authors : Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart-Gebhart M, Flamen P, Di Cosimo S
Year : 2013
Journal : J. Nucl. Med.
Volume : 54(11)
Pages : 1862-8

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

Authors : Kerklaan BM, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart M, Schellens JH, Awada A
Year : 2013
Journal : Cancer Chemother Pharmacol
Volume : 71(1)
Pages : 53-62

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Sandy H, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 377-84

Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges.

Authors : Alameddine RS, Otrock ZK, Awada A, Shamseddine A
Year : 2013
Journal : Curr Opin Oncol
Volume : 25(3)
Pages : 313-24

Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .

Authors : Zardavas D, Cameron D, Krop I, Piccart-Gebhart M
Year : 2013
Journal : Am Soc Clin Oncol Educ Book
Volume : null(null)

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24
Pages : 377-384

Clinical practice-changing trials: the HERA study paradigm.

Authors : Zardavas D, Ades F, de Azambuja E
Year : 2013
Journal : Expert Rev Anticancer Ther
Volume : 13(11)
Pages : 1249-56

Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.

Authors : Azim HA, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart-Gebhart M, Peccatori FA
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(1)
Pages : 73-9

Academic versus industry-driven research in upper gastrointestinal cancer: sinners and saints.

Authors : Hendlisz A, Charette N, Awada A, Deleporte A
Year : 2013
Journal : Curr Opin Oncol
Volume : 25(4)
Pages : 407-8

Emerging targeted agents in metastatic breast cancer.

Authors : Zardavas D, Baselga J, Piccart-Gebhart M
Year : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(4)
Pages : 191-210

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.

Authors : Ades F, Senterre C, de Azambuja E, Sullivan R, Popescu R, Parent F, Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(11)
Pages : 2897-902

Stratified Medicine: a call for action

Authors : Awada A, Annemans L, Broeckx D, Pauwels P, Simoens S, Van Belle S, van Cutsem E, Van Hoof E, De Greve J
Year : 2013
Journal : Belgian J Medical Oncology
Volume : 7(1)
Pages : 15-19

Second primary cancers in head and neck cancer patients: a challenging entity.

Authors : de Castro G, Awada A
Year : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pages : 203-4

Thérapies biologiques ciblées et cancer thyroïdien récidivant : enfin un standard thérapeutique ?

Authors : Lalami Y
Year : 2012
Journal : Onco-Hémato
Volume : 6(5)
Pages : 45-51

Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial.

Authors : Piccart-Gebhart M
Year : 2012
Journal : Ann Oncol
Volume : 23 Suppl 6
Pages : vi5-vi6

Clinical development of new formulations of cytotoxics in solid tumors.

Authors : Azim HA, Awada A
Year : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pages : 325-31

Význam biomarkerù v klinické onkologii

Authors : Klastersky J
Year : 2012
Journal : lekarsky Sbornik
Volume : sup1
Pages : 14-17

Percutaneous endoscopic jejunostomy in patients with gastroparesis following lung transplantation: feasibility and clinical outcome.

Authors : Toussaint E, Van Gossum A, Ballarin A, Le Moine O, Estenne M, Knoop C, Devière J, Arvanitakis M
Year : 2012
Journal : Endoscopy
Volume : 44(8)
Pages : 772-5

Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology.

Authors : Awada A, Vandone AM, Aftimos P
Year : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pages : 297-304